Drug evaluation: LB-80380 - A novel phosphonate nucleoside for the potential treatment of HBV infection

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 4, 2006, Pages 352-357

  Papatheodoridis, George V ^a   Manolakopoulos, Spilios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)GUANINE; ADEFOVIR; ANA 317; DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; LB 803400; LB 80366; LB 80372; LB 80373; LB 80397; LB 80398; PLACEBO; RNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATENT; PROTEIN BLOOD LEVEL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; GUANINE; HEPATITIS B; HUMANS; PHOSPHONIC ACIDS;

HEPATITIS B VIRUS;

EID: 33747477116     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. 63 Perspectives for the treatment of hepatitis B virus infections. De Clercq E INTJ ANTIMICROB AGENTS 1999 12 2 81-95
2. 29 Antiviral chemotherapy for the treatment of hepatitis B virus infections. Torresi J, Locamini S GASTROENTEROLOGY 2000 118 2 Suppl S83-S103
3. 77 Novel phosphonate nucleotides, LB80317 and its derivatives: Synthesis and anti-HBV activity. Choi J, Hwang J, Cho DG, Roh KY, Kim J, Cho WY, Kim GW, Chang HS, Cho YG, Ann SB, Kim YZ ICAAC 2002 42 Abs F1688
4. 18 Synthesis and determination of oral bioavailability of prodrugs of a novel phosphonate nucleotide, LB80317. Choi J, Hwang J, Cho DG, Roh KY, Kim J, Kim TG, Lee MK, Jung KH, Choi OH, Lee SW, Han MJ, Kim CM, Kim CH ICAAC 2002 42 Abs F1 689
5. 19 In vitro and in vivo activities of LB80380: A novel acyclic phosphonate nucleotide with potent anti-HBV activity. Kim J, Cho WY, Cho YG, Kim GW, Lee MK, Kim CM, Han MJ, Choi J, Hwang J, Cho DG, Roh KY, Kim YZ ICAAC 2002 42 Abs F1690
6. 21 Evaluation of mitochondrial toxicities of new phosphonate derivatives. Kim GW, Roh KY, Kim J ICAAC 2002 42 Abs F1691
7. 22 Cytotoxicities of LB80317 and its derivatives in Chinese hamster ovary cells expressing human renal organic anion transporter 1. Cho YG, Kim GW, Kim J ICAAC 2002 42 Abs F1692
8. 26 Pharmacokinetic and safety profiles of LB80380, a novel acyclic phosphonate nucleotide, as a new anti-HBV drug candidate. Kim SH, Choi ES, Jung K, Noh SH, Chung KH, Choi OH, Bu C, Lee SH, Park M, Kim J, Lee S ICAAC 2002 42 Abs F1693
9. 27 Discovery of a novel phosphonate nucleotide, LB80380: Synthesis, efficacy, Safety and pharmacokinetics. Kim J, Choi J, Kim YZ, Lee SH, Lee S, Kim I ICAAC 2002 42 Abs F1694
10. 43 Antiviral Research - 16th International Conference (Part I): HBV and HCV. Smee D IDDB MEETING REPORT 2003 April 27 - May 1
11. 51 Local new drugs approaching commercialization. PHARMA KOREANA 2003 13 4 29-31
12. 15 About LG Life Sciences - History: After spin-off. LG Life Sciences Ltd COMPANY WORLD WIDE WEB SITE 2001 September 1 http://www.lgls.co.kr
13. 08 Anadys Pharmaceuticals and LG Life Sciences enter into joint development and license agreement for LB80380 - ANA380 - A phase II hepatitis B compound. Anadys Pharmaceuticals Inc PRESS RELEASE 2004 April 19
14. 54 LB80317, a novel anti-HBV agent, is very potent against wild type as well as lamivudine-resistant HBV viruses. Kim J, Choi J-R, Kim YZ, Cho WY, Cho YG, Kim GW, Lee MK, Kim TG, Hwang J-T, Cho DG, Roh KY ANTIVIR RES 2003 57 3 A56
15. 57 LB80380, a novel nucleoside phosphonate, is a very potent anti-HBV agent. Kim J, Choi JR, Kim YZ, Lee SH, Lee S, Kim IC ANTIVIR RES 2003 57 3 A91
16. 91 Phase II progress for Anadys and LG's HBV drug. Anadys Pharmaceuticals Inc PRESS RELEASE 2004 September 14
17. 46 Anadys Pharmaceuticals and LG Life Sciences report results from completed phase I/II clinical trial of ANA380 (LB80380) for hepatitis B. Anadys Pharmaceuticals Inc, LG Life Sciences Ltd PRESS RELEASE 2004 November 01
18. 78 Anadys and LG's ANA-380 effective against HBV in phase II trial. Anadys Pharmaceuticals Inc PRESS RELEASE 2004 December 13
19. 05 A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent Choi JR, Cho DG, Roh KY, Hwang JT, Ahn S, Jang HS, Cho WY, Kim KW, Cho YG, Kim J, Kim YZ J MED CHEM 2004 47 11 2864-2869
20. 19 Anadys and Novartis to codevelop hepatitis drug. Anadys Pharmaceuticals Inc PRESS RELEASE 2005 June 02
21. 63 Novartis licenses rights to develop and commercialize new hepatitis treatment. Novartis AG PRESS RELEASE 2005 June 02
22. 04 Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection. Yuen MF, Kim J, Wong DKH, Ngai VWS, Yuen JCH, Lai CL J HEPATOL 2004 40 Suppl 1 133
23. 12 Anadys's ANA-380 reduces HBV viral load in phase II trial. Anadys Pharmaceuticals Inc PRESS RELEASE 2006 February 14
24. 65 Interim report for a phase II, multi-centre, dose-escalating study of LB8038/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV. Lai CL, Han KH, Yoon SK, Um SH, Yuen ME, Kim HS, Kim HR, Chung HC, Kim CR, Hsyu P, Averett D, Kim J J HEPATOL 2005 42 Suppl 2 31
25. 66 Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection. Yuen MF, Kim J, Averett D, Wong DKH, Kim CR, Kerr B, Ngai VWS, Yuen YCH, Lai CL HEPATOLOGY 2004 40 4 Suppl 1172A
26. 64 Current management of chronic hepatitis B. Papatheodoridis GV, Hadziyannis SJ ALIMENT PHARMACOL THER 2004 19 1 25-37
27. 66 Adefovir dlpivoxil added to on going lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Perrillo R, Hann-H-W, Mutimer D GASTROENTEROLOGY 2004 126 1 81-90
28. 68 Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Bommel F, Wuunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T HEPATOLOGY 2004 40 6 1421-1425
29. 77 Hepatitis B: An important public health issue. Maddrey WC J MED VIROL 2000 613 362-366
30. 18 Phase II, multi-centre, dose escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine resistant YMDD mutant HBV. Lai CL, Han KH, Yoon SK, Um SH, Yuen MF, Kim HS, Kim HR, Chung HC, Kim CR, Hsyu P, Averett D, Worland S, Kim J J HEPATOL SUPPL 2006 44 Suppl 2 S5 Abs 6